4 Best Peptides for Peyronie's Disease

What to Know Before Choosing a Peptide for Peyronie's Disease

Peyronie's Disease is a fibrotic condition. Fibrous scar tissue, called a plaque, forms inside the tunica albuginea of the penis, causing abnormal curvature, pain during erection, and in many cases erectile dysfunction. The root driver is abnormal collagen deposition, set in motion by persistent tissue injury and a cascade of inflammatory signaling primarily through a protein called TGF-beta1, which converts normal fibroblasts into collagen-overproducing myofibroblasts. That mechanism is why peptides enter the conversation at all: several of the compounds people reach for have demonstrated anti-fibrotic or collagen-remodeling properties in preclinical research, making the theoretical case coherent even when human trial data does not yet exist.

A compound earns a slot in this guide because people use it for Peyronie's Disease or are actively discussing using it, full stop. Evidence strength is not the filter here, because for this particular condition, no peptide has published human clinical trial data behind it as of 2026. Using an evidence threshold would produce an empty list, which would be neither honest nor useful. Instead, each compound's evidence, including the honest absence of it, is described plainly within its own entry. FDA-approved, telemedicine-prescribed, and research-only compounds are all eligible under that standard.

The numbers in front of each entry are a spine for the list, not a verdict. The order reflects how prominently each compound appears in the research and in real-world use, not a recommendation of one over another. Two people with Peyronie's Disease could look at this same list and reach very different conclusions based on disease stage, overall health, and what other approaches they are weighing. This guide maps the field. Turning that map into a personalized plan is what the MyPeptidePal app is built to do.

One piece of context belongs here before the entries begin. The only FDA-approved non-surgical treatment for Peyronie's Disease is collagenase clostridium histolyticum, an enzyme that directly cleaves and breaks down plaque collagen. Its Phase III trials across 832 men showed roughly a 34 percent reduction in penile curvature. It is not a peptide, it cannot be purchased online, and it must be administered by a qualified provider in an office setting. Anyone with confirmed Peyronie's Disease should be aware that a clinically validated treatment option exists and that consulting a urologist is the recommended first step regardless of what else is being considered.

1. BPC-157: The Most Discussed Option in Community Protocols

BPC-157, short for Body Protection Compound-157, is a synthetic pentadecapeptide, a chain of 15 amino acids derived from a protective protein found in gastric juice. It has one of the most active research profiles of any peptide in the tissue repair space, with studies in rodent models showing accelerated wound healing, tendon repair, and anti-inflammatory effects across a wide range of injury contexts. That breadth of preclinical activity is the primary reason it surfaces so consistently in discussions about Peyronie's Disease.

The proposed rationale for its use in Peyronie's is mechanistically coherent. Research in animal models has shown that BPC-157 can modulate TGF-beta1 activity, the same signaling protein that drives the conversion of normal fibroblasts into collagen-overproducing myofibroblasts at the core of plaque formation. It also appears to influence the MAPK and PI3K-Akt signaling pathways in ways that favor organized tissue repair over fibrotic scarring. There is preclinical evidence of oxidative stress reduction, which is relevant because reactive oxygen species drive ongoing collagen accumulation during the acute phase of the disease. It promotes organized Type I collagen rather than the disorganized collagen characteristic of plaque, and it supports angiogenesis, the growth of new blood vessels, which improves tissue perfusion in healing areas.

None of that has been studied in humans with Peyronie's Disease. The entire evidence base for BPC-157 in this specific application is preclinical and anecdotal. In the Peyronie's communities where it has been tried most systematically, the reported outcomes are predominantly negative. Community members describe trying BPC-157 at length, in some cases injecting it directly into or near the plaque, and finding no reduction in scar tissue and no correction of curvature. A number of those accounts note improvements in general recovery or subjective wellbeing that they attribute to the peptide, but explicitly state it did not address the underlying disease or shrink the plaque. The community consensus, drawn from substantial and repeated discussion across multiple forums and subreddits, is that BPC-157 does not produce disease regression for Peyronie's.

BPC-157 is a research chemical with no FDA approval for any human indication and no established safety profile for intralesional use in Peyronie's Disease specifically. Its growth-promoting and tissue-repair properties make it contraindicated in anyone with an active malignancy. It is available as both an injectable and in oral capsule form from research chemical suppliers. The evidence here is experiential rather than clinical, and the user-reported experience for this specific application is discouraging.

2. TB-500: The Repair Peptide Commonly Paired With BPC-157

TB-500 is a synthetic analog of Thymosin Beta-4, a naturally occurring peptide involved in actin regulation, tissue repair, and wound healing that is produced throughout the body. In general terms, it promotes cell migration toward injury sites, reduces local inflammation, and supports the remodeling of damaged tissue. It is widely used in athletic recovery contexts, and it is frequently paired with BPC-157 in a combination referred to in community circles as the Wolverine Blend. That pairing is the primary context in which TB-500 enters the Peyronie's Disease conversation.

The proposed mechanism follows from its general tissue-repair activity. The argument is that reducing inflammation and supporting healthy tissue remodeling at the plaque site could theoretically slow fibrosis progression or encourage a return toward more normal tissue architecture. Thymosin Beta-4 has shown anti-fibrotic properties in some animal models, and there is laboratory evidence that it modulates TGF-beta1 signaling, the same driver underlying plaque formation. In a condition whose core problem is pathological fibrosis following injury, the theoretical rationale for a peptide with anti-fibrotic effects is not implausible on its face.

The real-world experience reported by people who have actually tried it for Peyronie's Disease tells a different story. Community threads specifically evaluating TB-500, including accounts from users who administered it over extended periods and users who attempted direct injection into scar tissue, report uniformly that it produced no measurable change in plaque or curvature. Multiple independent accounts in the Peyronie's support community describe the compound as producing no effect on the disease, even when run alongside BPC-157 in the Wolverine Blend combination. As with BPC-157, some users report systemic benefits in recovery or inflammation control, but explicitly note that neither the plaque nor the curvature responded.

No human clinical trial has been published for TB-500 in Peyronie's Disease as of 2026. TB-500 is a research chemical, not FDA-approved for any indication, and is listed as a prohibited substance by the World Anti-Doping Agency for competitive athletes. Its general safety profile draws on data from other recovery contexts, where injection site reactions are the most commonly reported adverse effect. Active malignancy is a contraindication given its tissue-repair and growth-promoting properties.

3. GHK-Cu: The Collagen-Remodeling Copper Peptide

GHK-Cu is a naturally occurring copper-binding tripeptide, three amino acids carrying a copper ion, found in human blood plasma, saliva, and urine. Its concentrations decline significantly with age, and it has a long research history in wound healing and skin regeneration, where it plays a role in regulating collagen synthesis and remodeling. It holds a distinct position in the Peyronie's conversation because its proposed mechanism addresses a different part of the pathological process than BPC-157 or TB-500 do.

Where most peptides discussed for Peyronie's are positioned as anti-inflammatory or broadly anti-fibrotic, GHK-Cu is discussed primarily as a collagen remodeler. Its proposed action is to attract macrophages, the immune cells responsible for clearing and degrading disorganized tissue, to sites of abnormal collagen accumulation. The hypothesis is that drawing macrophages into the plaque area could facilitate breakdown of the disorganized collagen that makes up the scar and encourage its replacement with normally organized collagen. It also promotes angiogenesis through VEGF-related pathways, improving blood flow and oxygenation in tissue that has become fibrotic and relatively avascular. Some clinicians have taken this mechanistic logic seriously enough to offer GHK-Cu topical cream in combination with shockwave therapy as an experimental combination protocol, though no published clinical trial data supports this approach for Peyronie's specifically.

The evidence for GHK-Cu in Peyronie's Disease is limited. No human clinical trials specific to the condition exist as of 2026. Community reports are sparse compared to those for BPC-157, and the outcomes reported are unclear: some users suggest it as an option worth investigating, but no documented successful case studies appear in the reviewed Peyronie's communities. GHK-Cu is primarily discussed in the context of topical application, which carries lower systemic risk than injectable peptides and is a meaningful practical consideration for a sensitive anatomical site. It is widely available as a cosmetic topical ingredient, available as an injectable research chemical from research suppliers, and not FDA-approved for Peyronie's Disease or any other therapeutic indication.

4. Serrapeptase: The Fibrinolytic Enzyme in the PD Conversation

Serrapeptase occupies an unusual position in this list. It is technically a proteolytic enzyme, a protein-digesting biological catalyst derived from silkworm gut bacteria, rather than a peptide in the structural sense. It functions as a fibrinolytic agent, meaning it is claimed to break down fibrous and non-living tissue such as fibrin, blood clots, and scar material without affecting healthy living tissue. It enters Peyronie's Disease discussions partly because of that fibrinolytic rationale, which sounds directly applicable to a condition defined by fibrous plaque, and partly because it is available as an over-the-counter oral supplement in many countries, making it one of the lowest-barrier options in this space.

The proposed mechanism is conceptually straightforward: if the condition involves fibrous scar tissue buildup, an agent that dissolves fibrous tissue might reduce the plaque. That logic is why serrapeptase circulates in discussions about fibrotic and adhesive conditions generally. In practice, the evidence is much thinner than the mechanism would suggest. No clinical trials specific to Peyronie's Disease have been published. The broader human evidence for serrapeptase's fibrinolytic activity in deep tissue scar reduction is limited across all indications, and the specific claim that it can meaningfully dissolve an established penile plaque has not been evaluated in controlled research.

Community sentiment for serrapeptase in the Peyronie's space is cautious. Some anecdotal reports describe it as potentially worth trying, but the prevailing view is skeptical and calls for clinical evidence before drawing conclusions. Unlike BPC-157 and TB-500, which have been tried extensively by Peyronie's patients and returned predominantly negative reports, serrapeptase has generated less systematic experimentation in the community and correspondingly fewer accounts of either success or failure. It is available as an enteric-coated oral supplement in the US, classified as a dietary supplement rather than a drug, though it holds drug approval status in some European and Asian markets. Potential interactions with anticoagulant medications are worth noting given its fibrinolytic activity.

How These Peptides Compare

Frequently Asked Questions

Are any peptides FDA-approved for Peyronie's Disease?

No peptide is FDA-approved for Peyronie's Disease as of 2026. The only FDA-approved non-surgical pharmacological treatment for the condition is collagenase clostridium histolyticum, which is an enzyme, not a peptide. All of the compounds covered in this guide are either research chemicals, dietary supplements, or cosmetic ingredients when used in this context, and none carry FDA approval for this indication.

Why do people try peptides for Peyronie's if there is no clinical evidence?

Peyronie's Disease is underserved by conventional medicine, and the approved treatment involves in-office injections with a meaningful side effect profile that is not suitable for everyone. People exploring peptides are typically motivated by the theoretically coherent rationale for compounds with anti-fibrotic or collagen-remodeling properties in preclinical models, and by the limited availability of accessible alternatives. The gap between a plausible mechanism and a proven clinical outcome is where most of the Peyronie's peptide conversation lives.

What do communities that have tried these peptides report?

The verdict from people who have tried BPC-157 and TB-500 specifically for Peyronie's Disease is predominantly negative. Multiple threads in dedicated Peyronie's forums and subreddits describe running these compounds for extended periods, including attempts at direct injection near the plaque, with no reduction in scar tissue and no improvement in curvature. GHK-Cu and serrapeptase have fewer systematic reports, and neither has generated documented success stories in the reviewed communities.

How long before someone would know if a peptide was having an effect on Peyronie's?

There is no established timeline because no clinical trial has measured it for any peptide in this condition. Community members who have tried these compounds report running them for weeks to months without observing disease-level changes in plaque or curvature. The honest answer is that no rigorous measurement exists, and the community experience does not suggest a reliable timeframe has emerged.

Should someone with Peyronie's Disease consult a doctor before trying peptides?

Yes, and ideally a urologist familiar with Peyronie's Disease specifically. The disease has a well-characterized course, and the timing of any intervention matters, particularly the distinction between the acute inflammatory phase and the chronic stable phase. A urologist can discuss evidence-based options and provide context for where experimental approaches fit relative to interventions that have been studied in humans.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for Peyronie's Disease in one place.